Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
- PMID: 22707395
- DOI: 10.1002/hep.25889
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
Abstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and being overweight is a significant risk factor. The aim was to build an algorithm along with a scoring system for histopathologic classification of liver lesions that covers the entire spectrum of lesions in morbidly obese patients. A cohort of 679 obese patients undergoing liver biopsy at the time of bariatric surgery was studied. An algorithm for segregating lesions into normal liver, NAFLD, or nonalcoholic steatohepatitis (NASH) was built based on semiquantitative evaluation of steatosis, hepatocellular ballooning, and lobular inflammation. For each case, the SAF score was created including the semiquantitative scoring of steatosis (S), activity (A), and fibrosis (F). Based on the algorithm, 230 obese patients (34%) were categorized as NASH, 291 (43%) as NAFLD without NASH, and 158 (23%) as not NAFLD. The activity score (ballooning + lobular inflammation) enabled discriminating NASH because all patients with NASH had A ≥ 2, whereas no patients with A < 2 had NASH. This score was closely correlated with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P < 0.0001, analysis of variance [ANOVA]). Comparison of transaminase levels between patients with normal liver and pure steatosis did not reveal significant differences, thus lending support to the proposal not to include steatosis in the activity score but to report it separately in the SAF score. In the validation series, the interobserver agreement for the diagnosis of NASH was excellent (κ = 0.80) between liver pathologists. There was no discrepancy between the initial diagnosis and the diagnosis proposed using the algorithm.
Conclusion: We propose a simple but robust algorithm for categorizing liver lesions in NAFLD patients. Because liver lesions in obese patients may display a continuous spectrum of histologic lesions, we suggest describing liver lesions using the SAF score.
Copyright © 2012 American Association for the Study of Liver Diseases.
Similar articles
-
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes Surg. 2005 Mar;15(3):310-5. doi: 10.1381/0960892053576820. Obes Surg. 2005. PMID: 15826462
-
Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.Obes Surg. 2006 Dec;16(12):1584-93. doi: 10.1381/096089206779319392. Obes Surg. 2006. PMID: 17217634
-
Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.Chirurgia (Bucur). 2012 Nov-Dec;107(6):772-9. Chirurgia (Bucur). 2012. PMID: 23294957
-
Non-alcoholic steatohepatitis in children.Pediatr Transplant. 2004 Dec;8(6):613-8. doi: 10.1111/j.1399-3046.2004.00241.x. Pediatr Transplant. 2004. PMID: 15598336 Review.
-
[Role of liver biopsy in the diagnosis of NASH].Nihon Rinsho. 2006 Jun;64(6):1119-25. Nihon Rinsho. 2006. PMID: 16768119 Review. Japanese.
Cited by
-
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.Clin Mol Hepatol. 2016 Sep;22(3):327-335. doi: 10.3350/cmh.2016.0049. Epub 2016 Sep 25. Clin Mol Hepatol. 2016. PMID: 27729634 Free PMC article. Review.
-
Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review.Biomedicines. 2021 Apr 2;9(4):378. doi: 10.3390/biomedicines9040378. Biomedicines. 2021. PMID: 33918467 Free PMC article. Review.
-
Non-alcoholic fatty liver disease: the pathologist's perspective.Clin Mol Hepatol. 2023 Feb;29(Suppl):S302-S318. doi: 10.3350/cmh.2022.0329. Epub 2022 Nov 15. Clin Mol Hepatol. 2023. PMID: 36384146 Free PMC article. Review.
-
Anti-Diabetic and Cytotoxic Evaluation of Phlomis stewartii Plant Phytochemicals on Cigarette Smoke Inhalation and Alloxan-Induced Diabetes in Wistar Rats.Metabolites. 2022 Nov 17;12(11):1133. doi: 10.3390/metabo12111133. Metabolites. 2022. PMID: 36422273 Free PMC article.
-
Histological assessment based on liver biopsy: the value and challenges in NASH drug development.Acta Pharmacol Sin. 2022 May;43(5):1200-1209. doi: 10.1038/s41401-022-00874-x. Epub 2022 Feb 14. Acta Pharmacol Sin. 2022. PMID: 35165400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical